newsfilter
← Latest News
GlobeNewswire·

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing